Published in TB and Outbreaks Week, December 25th, 2001
"The company is pleased to add ethambutol to our portfolio of antibacterial products and plans to launch the product immediately," said Bruce L. Downey, Barr's chairman and CEO.
Myambutol is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.